6533b81ffe1ef96bd1277aad

RESEARCH PRODUCT

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

François HerrmannK. HöffkenG. KüstersAlbrecht LindemannH. G. FuhrFelicia Dr RosenthalKarin KolbeR H Mertelsmann

subject

medicine.medical_specialtyMitoxantroneDaunorubicinbusiness.industryLow dosemedicine.diseaseGastroenterologyMyelogenouschemistry.chemical_compoundLeukemiaRefractorychemistryInternal medicinemedicinePrimary treatmentbusinessCytosinemedicine.drug

description

Nineteen patients with relapsed or refractory acute myelogenous leukemia were treated with escalating doses of aclacinomycin (ACLA 20–30 mg/m2 daily for 5 days) and intermediate-dose cytosine arabinoside (Ara-C 1 g/m2 twice daily for 4 days). Most patients had received previous therapy with high- or intermediate-dose Ara-C plus mitoxantrone (HAM, IAM) and TAD (6-thioguanine, standard-dose cytosine arabinoside, and daunorubicin). Four patients had had repeated relapses and another three were treated for primary treatment failure following induction with HAM or I AM.

https://doi.org/10.1007/978-3-642-75720-4_2